0001968202-24-000023.txt : 20240104
0001968202-24-000023.hdr.sgml : 20240104
20240104160703
ACCESSION NUMBER: 0001968202-24-000023
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOLDSTEIN JOSEPH L
CENTRAL INDEX KEY: 0001225474
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 24511857
MAIL ADDRESS:
STREET 1: DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS
STREET 2: 5323 HARRY HINES BLVD
CITY: DALLAS
STATE: TX
ZIP: 75390
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-01-02
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001225474
GOLDSTEIN JOSEPH L
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
0
0
0
0
Common Stock
2024-01-02
4
A
0
135
0.0
A
6382
D
Non-Qualified Stock Option (right to buy)
888.34
2024-01-02
4
A
0
1607
0.0
A
2034-01-02
Common Stock
1607
1607
D
Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
/s/**Joseph L. Goldstein
2024-01-04